Trial Profile
A Phase I, Open-Label, Multi-Center Study of CKD-581 in Combination With Lenalidomide and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2022
Price :
$35
*
At a glance
- Drugs Alteminostat (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Chong Kun Dang
- 20 Feb 2020 Planned End Date changed from 19 Nov 2019 to 30 Sep 2021.
- 20 Feb 2020 Planned primary completion date changed from 29 Jun 2018 to 30 Jun 2020.
- 06 Nov 2019 Results (n=10; As of 11th July 2019) released at the 61st Annual Meeting and Exposition of the American Society of Hematology.